-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on Abbott Laboratories, Raises Price Target to $169

Benzinga·01/05/2026 15:02:04
Listen to the news
Barclays analyst Matt Miksic maintains Abbott Laboratories (NYSE:ABT) with a Overweight and raises the price target from $162 to $169.